Medication

House Speaker Nancy Pelosi of Calif., speaks during a news conference on Capitol Hill in Washington, Thursday, Oct. 31, 2019. (AP Photo/Susan Walsh)
November 05, 2019 - 1:13 pm
WASHINGTON (AP) — The White House has concluded that House Speaker Nancy Pelosi's plan authorizing Medicare to negotiate drug prices is "unworkable" and President Donald Trump will instead support bipartisan legislation in the Senate, a senior White House official said Tuesday. Despite the House...
Read More
House Speaker Nancy Pelosi of Calif., speaks during a news conference on Capitol Hill in Washington, Thursday, Oct. 31, 2019. (AP Photo/Susan Walsh)
November 05, 2019 - 12:27 pm
WASHINGTON (AP) — The White House says House Speaker Nancy Pelosi's plan authorizing Medicare to negotiate prescription drug prices is "unworkable" and President Donald Trump is instead supporting bipartisan Senate legislation. A senior White House official tells The Associated Press the...
Read More
FILE - In this Nov. 8, 2018, file photo, the U.S. Medicare Handbook is photographed, in Washington. A new study finds that more than half of seriously ill Medicare enrollees _ 53% _ struggle to pay their medical bills. Prescription drugs are the leading problem. The researchers who wrote Monday’s report in the journal Health Affairs were surprised by their findings, since Medicare is considered relatively good coverage. (AP Photo/Pablo Martinez Monsivais, File)
November 04, 2019 - 4:03 pm
WASHINGTON (AP) — More than half of seriously ill Medicare enrollees face financial hardships with medical bills, with prescription drug costs the leading problem, according to a study published Monday. The study in the journal Health Affairs comes as legislation to curb drug costs for seniors...
Read More
FILE- This May 1, 2018, file photo shows Merck corporate headquarters in Kenilworth, N.J. Merck & Co. reports financial earns Tuesday, Oct. 29, 2019. (AP Photo/Seth Wenig, File)
October 29, 2019 - 7:47 am
Big jumps in sales of Merck's top two blockbuster drugs drove revenue up 15%, but higher spending across the board pushed profits down 3% in the third quarter. Merck still easily beat Wall Street forecasts and boosted its forecast for the year. The quarter were dominated again by advanced cancer...
Read More
FILE- This May 1, 2018, file photo shows Merck corporate headquarters in Kenilworth, N.J. Merck & Co. reports financial earns Tuesday, Oct. 29, 2019. (AP Photo/Seth Wenig, File)
October 29, 2019 - 7:25 am
KENILWORTH, N.J. (AP) — Merck is reporting a very strong third quarter with sales of one of its key drugs soaring 62%. The pharmaceutical company on Tuesday posted earnings of $1.9 billion, or 74 cents per share. Removing one-time costs, earnings were $1.51 per share, easily topping Wall Street...
Read More
FILE - In this Aug. 14, 2014, file photo, a man exhales vapor as he demonstrates the use of his electronic cigarette in Salt Lake City. Several Utah vape shops are suing the state's Department of Health over its emergency rule restricting the sale of flavored e-cigarettes. The retailers claim in a lawsuit filed Monday, Oct. 21, 2019, in Utah state court that there is no evidence to suggest flavored e-cigarettes are causing lung damage and that the new rule could hurt business. (AP Photo/Rick Bowmer, File)
October 26, 2019 - 12:40 pm
More than medication is being collected during Saturday's National Prescription Drug Take Back Day. For the first time, vaping devices and cartridges also are being accepted for disposal. The federal Drug Enforcement Administration says the change stemmed from concerns across about illnesses and...
Read More
October 22, 2019 - 10:15 pm
WASHINGTON (AP) — A powerful House panel has approved House Speaker Nancy Pelosi's legislation to lower prescription drug prices for seniors and working-age people. The Ways and Means committee voted Tuesday along party lines, moving the bill closer to floor action. It fulfills a long-sought...
Read More
FILE - In this Aug. 14, 2018 file photo, Dr. William Burke goes over a PET brain scan at Banner Alzheimers Institute in Phoenix. The drug company Biogen Inc. says it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of the most common form of dementia. The announcement Tuesday, Oct. 22, 2019, is a surprise because the company earlier this year stopped two studies of the drug, called aducanumab, after partial results suggested it was not working. (AP Photo/Matt York, File)
October 22, 2019 - 6:44 pm
Biogen Inc. said Tuesday it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of the most common form of dementia. The announcement was a surprise because the drug company earlier this year stopped two...
Read More
FILE - In this Aug. 14, 2018 file photo, Dr. William Burke goes over a PET brain scan at Banner Alzheimers Institute in Phoenix. The drug company Biogen Inc. says it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of the most common form of dementia. The announcement Tuesday, Oct. 22, 2019, is a surprise because the company earlier this year stopped two studies of the drug, called aducanumab, after partial results suggested it was not working. (AP Photo/Matt York, File)
October 22, 2019 - 4:13 pm
Biogen Inc. said Tuesday it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of the most common form of dementia. The announcement was a surprise because the drug company earlier this year stopped two...
Read More
FILE - In this Aug. 14, 2018 file photo, Dr. William Burke goes over a PET brain scan at Banner Alzheimers Institute in Phoenix. The drug company Biogen Inc. says it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of the most common form of dementia. The announcement Tuesday, Oct. 22, 2019, is a surprise because the company earlier this year stopped two studies of the drug, called aducanumab, after partial results suggested it was not working. (AP Photo/Matt York, File)
October 22, 2019 - 10:40 am
The drug company Biogen Inc. said Tuesday it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of the most common form of dementia. The announcement was a surprise because the company earlier this year...
Read More

Pages